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Abstract
Background: WHO has a pivotal role to play as the leading international agency promoting good practices in
health and human rights. In 2005, mifepristone and misoprostol were added to WHO’s Model List of Essential
Medicines for combined use to terminate unwanted pregnancies. However, these drugs were considered
‘complementary’ and qualified for use when in line with national legislation and where ‘culturally acceptable’.
Discussion: This article argues that these qualifications, while perhaps appropriate at the time, must now be
removed. First, compelling medical evidence justifies their reclassification as a ‘core’ essential medicine. Second,
continuing to subjugate essential medicines for medical abortion to domestic law and cultural practices is incoherent
with today’s human rights standards in which universal access to these medicines is an inextricable part of the right to
sexual and reproductive health, which should be supported and realised through domestic legislation.
Conclusion: This article shows that removing such limitations will align WHO’s Model List of Essential Medicines with
the mounting scientific evidence, human rights standards, and its own more recently developed policy guidance. This
measure will send a strong normative message to governments that these medicines should be readily available in a
functioning and human-rights-abiding health system.
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Background
Complications of unsafe abortion are still among the top
five causes of direct maternal mortality. Maternal
mortality claims the lives of 289,000 women annually,
while complications during childbirth result in 5.8
million serious injuries every year and deaths due to
unsafe abortion remain close to 13% of all maternal
deaths [1]. Unsafe abortion remains a serious human
rights and public health problem which is estimated to
cause 47,000 maternal deaths and five million maternal
disabilities annually [1]. Improving access to family plan-
ning and to safe abortion services prevents injury and
death that affects women trying to terminate unwanted
pregnancies [2–4].
WHO has a primary role to play as the leading inter-
national agency promoting good practices in health and
human rights. The year 2005 marked a major milestone
for access to safe abortion services when the combin-
ation therapy mifepristone and misoprostol was included
by WHO its Model List of Essential Medicines [5].
Mifepristone and misoprostol capsules can be self-
administered to safely induce a discrete and non-
invasive medical abortion in pregnant women up to
12 weeks of gestation.1 [6, 7] The combination was listed
as a complementary medicine, following the opinion of
the Expert Committee at the time that specialised health
care facilities or services may be needed for its safe and
effective use [8]. Moreover, WHO’s 2012 guidelines on
safe abortion sent a strong message from an UN agency
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by endorsing the medical evidence and compelling hu-
man rights rationale for providing safe abortion [7].
Taken together, these endorsements from the public
health community further legitimised medical abortion
as an important clinical choice for women- one that
should be part of a basic minimum package of medicines
and available in functioning health systems.
In 2005, WHO’s then-Director General added a
note to the entry on the Model List that read ‘[for
use] where permitted under national law and where
culturally acceptable’ (p. 37) [5, 9]. Such a condition-
ality risks offering a loophole to governments wary of
embracing medical abortion, or abortion in general.
Mifepristone and misoprostol’s addition to WHO’s
Model List was lauded as an opportunity for medical
abortion to reach women in rural and low-resourced
settings who may otherwise be unable to seek safe
surgical abortion [9]. In 2006, the more specific Inter-
agency List of Essential Medicines for Reproductive
Health also included mifepristone and misoprostol
with the same adjacent note [10].
In 2016, the Committee on Economic, Social and
Cultural Rights (CESCR), a collection of human rights
experts tasked with interpreting these rights, asserted
that abortion services are an integral part of the right to
health in its ground-breaking interpretation of the right
to sexual and reproductive health, General Comment
No. 22 (para. 56-57) [11].
Since WHO’s initial move to improve access to mife-
pristone and misoprostol, mounting evidence of their
safety combined with the evolution in human rights law
now demand a revised approach. However, the status of
mifepristone and misoprostol is unchanged in WHO’s
20th Model List of Essential Medicines published in
March 2017 [12]. The time has come for WHO to re-
move the restriction of specialist supervision and to
move the combination to the core list of the Model List
of Essential Medicines and removing the qualifications.
These moves would send a strong signal to Member
States - many of which are signatories to the International
Covenant on Economic, Social and Cultural Rights
(ICESCR) and therefore have the responsibility to protect
and promote the right to health - to improve coherence
between their international commitments and domestic
fulfilment of the right. Enhancing policy coherence for
sustainable development is a target in Sustainable Devel-
opment Goal no. 17. These issues warrant thoughtful dis-
cussion by WHO’s Expert Committee on Selection and
Use of Essential Medicines and support from the broader
sexual and reproductive health and rights community.
In the following sections of this paper we first explore
the integration of the public health and legal frameworks
in light of the CESCR’s recent interpretation of sexual
and reproductive health. Thereafter the arguments for
two recommendations are presented: 1) mifepristone
and misoprostol should be reconsidered as ‘core’
essential medicines rather than ‘complementary’ prod-
ucts; and 2) universal access to these medicines should
be in line with human rights law and not unduly
restricted by domestic law or cultural practices.
Discussion
Integrating the public health and legal frameworks for
sexual & reproductive health
Essential medicines for medical abortion
Domestic governments can greatly improve the efficient
use of health resources by selecting a narrow list of essen-
tial medicines, which are defined as ‘those that satisfy the
priority healthcare needs of the population’ (p. 15) [13].
According to WHO, essential medicines are used for dis-
ease prevention, treatment, and control, and are applicable
to most chronic and acute diseases. WHO’s definition
states that essential medicines should be available in a
well-functioning health system to all who need them, at a
price the patient and the community can afford. When
selecting which medicines are essential the WHO pays
due regard to disease prevalence, but also to efficacy, safety
and comparative cost-effectiveness [13].
WHO’s Model List of Essential Medicines is a
standard-setting instrument for national medicines se-
lection with a strong normative influence on decisions
about medicines supply, distribution, and reimburse-
ment. Described as an advocacy tool with an ‘oper-
ational, educational, and symbolic’ character, the Model
List is simultaneously a guide for policy makers and
program managers to a priority medicines requiring at-
tention, an educational tool for decision makers and
healthcare professionals about medicines selection and
use, and a symbol of ‘worldwide recognition’ for key
medicines [14, 15]. Although the Model List is not le-
gally binding on governments, its authority directs
policies ranging from medicines production to reim-
bursement decisions, even in a national court of law.
WHO’s guidelines on safe abortion adopt and
promote a human rights-based approach to related
laws and policies. The guidelines point to the growing
medical evidence and compelling human rights ra-
tionale for providing safe abortion. WHO has recog-
nised that almost every abortion-related death and
disability could have been prevented through the
provision of safe, legal induced abortion and care for
complications (p. 1) [7]. In that line, WHO recom-
mends that laws and policies on abortion should pro-
tect women’s health and their human rights and that
regulatory, policy and programmatic barriers that hin-
der access to and timely provision of safe abortion
care should be removed (p. 9) [7].
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Human right to sexual & reproductive health
The right to health, affirmed most prominently in the
1966 International Covenant on Economic, Social, and
Cultural Rights, requires governments to take action to
assure maternal, child, and reproductive health. In 2000,
human rights experts on the Committee on Economic,
Social, and Cultural Rights (CESCR) adopted an authori-
tative interpretation of States’ responsibilities to assure
to all the highest attainable standard of health, General
Comment No. 14. In this document measures to combat
maternal morbidity and mortality include ‘sexual and re-
productive health services, including access to family
planning, pre- and post-natal care, emergency obstetric
services’ (para. 14) [16].
In 2016, the Committee on Economic, Social, and
Cultural Rights extensively addressed States’ legal duties
the right to sexual and reproductive health in its General
Comment No. 22. This Comment affirms that this right
is an integral part of the right to health- and is inter-
dependent on a series of human rights to life, personal
dignity, and others- that has enjoyed longstanding recog-
nition based on already existing international human
rights instruments. State parties to the ICESCR have the
obligation to respect the right to sexual and reproductive
health, which includes not limiting or denying access to
health services such as abortion, or maintaining laws or
practices that criminalise abortion, or requiring third-
party authorisation to access contraception or abortion
or excluding services such as abortion from publicly or
donor- funded programmes. Therefore, States parties are
duty-bound to facilitate access to safe abortion services
including by aligning domestic law and healthcare pack-
ages with current human rights standards.
The Convention on the Elimination of All Forms of
Discrimination Against Women (CEDAW) states that
affirmative measures need to be taken to eliminate dis-
crimination against women in the field of health care in
order to ensure, on a basis of gender equality, access to
health care services, including those related to family
planning (p. 13) [17]. General Recommendation No. 24
forbids states from restricting access to health services
or clinics to women “because they are women” or crim-
inalise health services that only women need or punish
women who seek those services [18]. The UN Commit-
tee on the Elimination of All Forms of Discrimination
Against Women has repeatedly considered “that failure
of a State party to provide services and the criminalisa-
tion of some services that only women require is a viola-
tion of women’s reproductive rights and constitutes
discrimination against them.” [19].
Fulfilling this right bestows upon States the core obli-
gation to provide medicines essential for sexual and
reproductive health based on the WHO Model List of
Essential Medicines (para. 49(g)) [11]. General Comment
No. 22 specifically requires States to ensure the availabil-
ity of essential medicines for abortion and post-abortion
care (paras. 13 & 49(g)) [11]. The prominence of the
Model List in General Comment 22 and other human
rights jurisprudence illustrates its global authority and
capacity for normative influence on Member States.
Removing the ‘complementary’ designation: mifepristone
and misoprostol qualify as ‘core’ essential medicines
Evidence substantiating mifepristone and misoprostol’s
safety no longer warrants specialist medical care and jus-
tifies moving the combination therapy to the core list of
essential medicines.
By 2005, mifepristone and misoprostol had been
proven safe, effective and convenient to induce medical
abortion. As the evidence base pointed to higher risks of
minor adverse effects, such as longer duration of the
bleeding compared to surgical abortion, WHO recom-
mended the combination therapy be used under close
medical supervision. Thus, mifepristone and misoprostol
were entered on WHO’s complementary list. A comple-
mentary essential medicine is ‘for priority diseases which
are efficacious, safe and cost-effective but not necessarily
affordable, or for which specialised health care facilities
or services may be needed’ (p. 20) [13].
The notion that these drugs warranted additional
safety measures stems from the dearth of evidence from
outside a research setting in the early days after its ap-
proval [20]. While the inclusion of these drugs in the
complementary list was once likely a precautionary
measure in a data-poor age, several studies have ren-
dered such precaution unnecessary. Several studies
confirmed that (i) abortion induced with misoprostol is
safer than when induced by other means, and (ii) a re-
duction in the complications of unsafe abortion is
observed over time, in parallel with an increase in the
sales of misoprostol [21–24]. Moreover, the Mifeprex
Risk Evaluation and Mitigation Strategy (REMS) Study
Group affirms that a wealth of evidence now demon-
strates mifeprostone’s effectiveness and safety [20]. Such
substantive evidence exists that the Mifeprex REMS
Study Group has recently called to revise the set of
safety restrictions imposed on mifepristone and miso-
prostol in the US, stating that the safety measures are
disproportionate to the low safety risks, and in some
cases, the measures are not legitimate to achieve their
objective [20].
In the 2012 WHO publication titled Safe Abortion:
Technical and Policy Guidance for Health Systems,
mifepristone and misoprostol are not only endorsed as a
safe and reliable combination therapy for medical abor-
tion, but also exempt from routine follow-up care in the
absence of complications (p. 3) [7]. Aiken et al. recently
reported low rates of adverse events experienced by
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women who received self-sourced medical abortion
through telemedicine. In this study women self-
identified potentially serious adverse events and most
sought medical attention when advised to do so; no
deaths were reported [25].
Reclassifying mifepristone and misoprostol as ‘core’
essential medicines on the Model List sends a clear mes-
sage to WHO Member States that these therapies do
not require specialist medical care for their safe and
effective use. However, maintaining mifepristone and
misoprostol on the complementary list in the absence of
compelling safety concerns would indulge the trend to
over-medicalise abortion services, which has historically
obstructed access the service [26].
Subjugating essential medicines for medical abortion to
domestic law: an incoherent approach
Subjecting the use of mifepristone and misoprostol for
medical abortion to national law is redundant, as pre-
sumably all governments exercise their discretion to use
medicines on the Model List in a manner congruent
with their domestic laws. More worrying is the fact that
in 2005 the global agency for health policy, WHO, saw
fit to specify that only medicines for medical abortion
and emergency contraception in emergency health kits
for refugee camps must comply with domestic law [9].
Curiously, this legal caveat was not explicitly stated in
relation to other contentious therapies, such as metha-
done for drug addiction (p. 33-34) [5].
Removing the guidance that mifepristone and misopros-
tol use must comply with national law will limit States’
margin of discretion to sidestep their human rights
obligations. The right to health standards clarified in the
2016 General Comment No. 22 indicate that national law
must be brought in line with human rights obligations
[27]. Governments have the obligation under human rights
law to repeal or eliminate laws, policies and practices that
criminalise, obstruct or undermine an individual’s or a
particular group’s access to health facilities, services, goods
and information, including abortion (para. 35) [11]. More-
over, scholars including those on the Lancet Commission
on Women and Health emphasise the need for ‘an
enabling social, legal, and regulatory environment’ to
respond to women and girls’ health needs and rights [1].
The Commission on the Status of Women continues to
demand that states strengthen their normative, legal, and
policy frameworks in this field [28].
Domestic law does not universally embrace medical
abortion [29–31]. Both human rights and public health
standards should complement one another and encourage
Member States to move towards a coherent approach.
Extensive literature shows that barring abortion does
not stop women from terminating unwanted
pregnancies, it only makes abortion considerably more
dangerous (p. 32) [7]. Unsafe abortion mainly endangers
women in countries where it is highly restricted by law
and women in countries where, although legally permit-
ted, safe abortion is not easily accessible [2]. Clandestine
abortions contribute substantially to maternal morbidity
and death worldwide [32]. Moreover, patients seeking
safe abortion to end an unwanted pregnancy are often
marginalised and can be made vulnerable by restrictive
national abortion laws or inaccessible abortion services.
It is precisely these patients who WHO’s Model List
should strive to serve by unequivocally endorsing mife-
pristone and misoprostol as essential components of
every health system.
Reducing the global maternal mortality ratio is one of
the targets of the Sustainable Development Agenda
adopted by the UN and mortality caused by unsafe abor-
tion has long been one of the obstacles to its achievement.
Even without concerted efforts to make these medicines
more available, women worldwide are using them and
they have saved thousands of lives [33–35]. The possibil-
ities offered by mifepristone and misoprostol to prevent
these avoidable deaths and health consequences should be
accessible to all who can benefit from them.
Suggesting that restrictive domestic law on abortion
justifies governments’ overt disregard or subtle apathy
for universal access to mifepristone and misoprostol is
incongruous with current human rights standards.
Adopting domestic laws consistent with international
treaties they have ratified demonstrates a government’s
commitment to realise sexual and reproductive health
and rights, while maintaining restrictions or expanding
them constitute impermissible barriers and potentially a
retrogressive measure that violates international human
rights law [28]. Legal codification, a recognised indicator
of these rights, may be the first step in improving the
respect, protection and fulfilment of these rights in
practice [36].
WHO has long recognised that the safety of abortion is
directly associated with less restrictive legal settings. In its
2012 publication Safe Abortion: Technical and Policy
Guidance for Health Systems, WHO comments on the
public health and human rights rationale stating ‘[w]here
legislation allows abortion under broad indications, the
incidence of and complications from unsafe abortion are
generally lower than where abortion is legally more
restricted.’ (p. 17) [7]. The report continues to cite recom-
mendations to States from UN committees to ‘reform laws
that criminalise medical procedures that are needed only
by women and that punish women who undergo these
procedures, both of which are applicable in the case of
abortion’ (p. 89 & box 4.1) [7]. Unequivocally WHO
affirms ‘Given the clear link between access to safe
abortion and women’s health, it is recommended that laws
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and policies should respect and protect women’s health
and their human rights’ (p. 90) [7].
A coherent public health and human rights approach
would confer an unfettered endorsement to essential
medical abortion medicines, regardless of any possible
limitations in domestic law and consonant with WHO’s
own mandate to advance the right to health and its
policy guidance supporting safe abortion.
Repeal the cultural acceptability limitation to
universalise access to essential medicines for medical
abortion
The WHO Model List qualifies the use of essential
medicines for medical abortion where they are culturally
acceptable. This limitation should also be removed for
the following three reasons.
First, the CESCR identifies that health services must
be culturally acceptable and respectful (para. 12(c)) [16].
It is reasonable to expect that States parties observe the
CESCR’s guidance in the regular discharge of their re-
sponsibilities. Therefore, an explicit caveat in the WHO
Model List about the use of any essential medicine in
line with cultural norms is redundant.
Second, cultural acceptability of health services does not
supersede States’ ‘core obligation’ to provide essential
medicines. The CESCR’s interpretation affirms ‘core
obligations’ as the nucleus of the right to health [16, 37].
Core obligations are fundamental basic minimums that
must be realised to give meaning to the right to health;
they serve as the foundation on which other aspects of the
right are built [38, 39]. Additionally, the CESCR states that
ideologically-based policies or practices, such as the
refusal to provide services based on conscience, must not
be a barrier to accessing services (para. 14) [11]. There-
fore, a human rights approach suggests States are not jus-
tified in denying the provision of ‘core’ health services,
such as essential medicines for medical abortion, when
they do not conform with some restrictive cultural norms.
Third, numerous UN bodies have long acknowledged
that violations of women’s right to health, such as lack
of access to health goods and services, are often justified
by references to culture or religion. Cultural acceptabil-
ity is an element of the right to health that guides its
shape in response to the local context but should not be
misused to challenge the universality of women’s rights
[16]. The UN Special Rapporteur in the field of cultural
rights has recently warned of extremism that rejects the
universality of human rights, aims to limit the enjoy-
ment of women’s human rights and restrict sexual and
reproductive rights under the label of ‘purity’ and
‘modesty’ [40]. States have an obligation to eradicate
cultural practices that result in human rights violations
such as barriers to access essential medicines for repro-
ductive health [16, 17]. Therefore, the WHO Model List
should not subordinate essential medicines for medical
abortion to their cultural acceptability. Instead, those
cultural practices should be modified in order to ad-
vance universal access to sexual and reproductive health.
Conclusion
Ending the silent pandemic of unsafe abortion is an urgent
public health and human rights imperative [2, 41]. WHO
should align the pharmaceuticals entry for medical abor-
tion on its Model List with the scientific evidence, human
rights standards, and its own more recently developed
policy guidance. The safety and efficacy of first trimester
medical abortion with mifepristone and misoprostol is
now better documented than when the combination was
first introduced to the Model List [7]. Providing essential
medicines for sexual and reproductive health is a core
human rights obligation. In addition, access to such im-
portant life-saving drugs must not be explicitly nor impli-
citly subjected to restrictive domestic laws or cultural
norms. Any restriction to access mifepristone and miso-
prostol for medical abortion before 12 weeks of gestation
would be tantamount to a violation of international
human rights law. WHO’s leadership is imperative to
signal that mifepristone and misoprostol are part of a
legitimate and inviolable reproductive healthcare package
that must be strengthened, rather than subjugated, by na-
tional law or cultural practices. WHO’s Expert Committee
on Selection and Use of Essential Medicines is in a unique
position to bridge the gap between human rights law and
WHO policy to respect and fulfil sexual and reproductive
health in practice.
Endnotes
1Misoprostol can be administered vaginally or sublin-
gually. According to WHO Guidelines on Safe Abortion,
strong evidence supports the use of the combination
therapy up to 9 weeks of gestation and after 12 weeks of
gestation [7]. Evidence from Uruguay indicates the com-
bination therapy can be safely used up to 12 weeks of
gestation [6].
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